{"Clinical Trial ID": "NCT00450866", "Intervention": ["INTERVENTION 1:", "Epothilone B: Group A", "Group A: Patupilone is given as a single intravenous infusion for 20 minutes once every 3 weeks. Patupilone is given at a dose of 10 mg/m2 (q3 weeks) with real body weight.", "INTERVENTION 2:", "Epothilone B: Group B", "Group B: an exploratory cohort of patients with leptomenal metastases (LMDs) or asymptomatic metastases of the unirradiated brain from breast cancer (BCBM). Patupilone will be administered as a single intravenous infusion for 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3 weeks) with real body weight."], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Histologically or cytologically confirmed breast carcinoma", "- CNS metastases (i.e., cerebral parenchymal lesions and/or leptomenesis), meeting 1 of the following criteria:", "Recurrent or progressive CNS metastases after whole brain radiation therapy", "If only an evaluable CNS progression site has already been treated with stereotactic radiosurgery, radiological necrosis should be excluded by radiography (e.g., positron emission tomography or magnetic resonance spectroscopy) or histological evaluation.", "Newly diagnosed, untreated, asymptomatic or leptomenic brain metastases", "The patient should be neurologically stable, as demonstrated by a stable dose of steroids and anticonvulsants for one week prior to obtaining gadolinium-enhanced brain MRI and/or one week prior to initiation of study therapy.", "No CNS complication requiring urgent neurosurgical intervention (e.g. resection or shunt placement)", "Unspecified hormonal receptor status", "CHARACTERISTICS OF PATIENTS:", "Men or women", "\u2022 Menopausal status not specified", "Karnofsky's performance status 60-100%", "Life expectancy 3 months", "Absolute number of neutrophils > 1500/mm^3", "Hemoglobin > 9.0 g/dL", "Number of platelets > 100 000/mm^3 (red blood cell transfusion and permitted repeated evaluation)", "Bilirubine < 1.5 times the upper limit of normal (ULN)", "ASAT and ALT < 2.5 times LSN", "Alkali phosphatase < 2.5 times ULN", "Creatinine < 1.5 times ULN", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception during and for 3 months after completion of study therapy.", "No known hypersensitivity to epothilones", "No peripheral neuropathy > grade 1", "No unsolved diarrhea in the last 7 days", "Grade 0 diarrhoea required at the start of the study", "No concomitant serious medical disease (e.g. HIV positivity or active hepatitis B or C)", "No severe heart failure (e.g., New York Heart Association Class III-IV heart disease) with uncontrolled and/or unstable heart or coronary disease", "No uncontrolled acute or chronic active or suspected infections, including abscesses or fistulas", "No other malignancy in the last 3 years, except non-melanoma skin cancer, prostate cancer or cervical cancer treated curatively", "No history of non-compliance with medical plans or of incapacity or refusal of return for all planned visits", "No contraindications to MRI, including any of the following:", "- Picemaker.", "- Ferromagnetic implants", "Claustrophobia", "Extreme obesity", "THERAPE PRIOR CONCURENT:", "See Disease Characteristics", "More than 2 weeks since previous non-cytotoxic drugs (e.g., targeted small molecule drugs) and recovered", "More than 3 weeks since prior cytotoxic chemotherapy (6 weeks for nitrosourea or mitomycin C) and recovered", "More than 3 weeks since previous intracranial surgery and recovered", "More than 4 weeks since previous radiotherapy and recovered", "More than 4 weeks since previous major surgery", "More than 28 days since previous experimental compounds or medicinal products", "No previous epothilones", "No concomitantly known diarrhoeal agents", "No other competing anticancers, including experimental agents, biological agents or chemotherapy", "No other concomitant experimental treatment", "- Concomitant hormone and/or trastuzumab (Herceptin\u00ae) are allowed", "No coumadin or other concomitant agent containing warfarin", "A low dose of Coumadin\u00ae ( 1 mg) for prophylactic maintenance of licensed pipes or residential harbours", "No simultaneous radiotherapy for central metastases (e.g., vertebral or mediastinal metastases)", "\u2022 Simultaneous radiotherapy for local peripheral metastases is not used as permitted marker lesions", "No prophylactic hematopoietic growth factor concomitantly during course 1", "No concomitant herbal or non-traditional medicinal products"], "Results": ["Performance measures:", "Central Nervous System (CNS) Survival without progression (SPF)", "The number of patients who are documented for progression-free survival at 3 months after treatment. Absence of progression is defined as an increase of <25% in the tumour area.", "The PFS will be measured from the date of entry into the trial to the date of documented progression of brain metastases or death.", "Duration: 3 months after treatment", "Results 1:", "Title of the arm/group: Epothilone B: Group A", "Group A: Patupilone will be given as a single intravenous infusion for 20 minutes, once every 3 weeks. Patupilone will be given at a dose of 10 mg/m2 (q3 weeks) with real body weight.", "Total number of participants analysed: 45", "Type of measurement: Number", "Unit of measurement: participants 12", "Results 2:", "Title of the arm/group: Epothilone B: Group B", "Group B: An exploratory cohort of patients with leptomeninged metastases (LMD) or non-irradiated asymptomatic brain metastases from breast cancer (BCBM). Patupilone will be administered as a single intravenous infusion for 20 minutes once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3 weeks) with real body weight.", "Total number of participants analysed: 10", "Type of measurement: Number", "Unit of measurement: participants 2"], "Adverse Events": ["Undesirable Events 1:", "Total: 18/55 (32.73 per cent)", "Anemia * 1/55 (1.82%)", "Neutropenia * 1/55 (1.82%)", "Dehydration * 6/55 (10.91%)", "Diarrhoea * 8/55 (14.55%)", "Haemorrhage, upper GI * 1/55 (1.82%)", "Ileus, IG (functional obstruction of the intestine, i.e. neuroconstipation) * 1/55 (1.82%)", "Nausea * 1/55 (1.82%)", "Pain - Abdomen NOS (not elsewhere specified) * 1/55 (1.82%)", "Ulcer, GI - Duodenum * 1/55 (1.82%)", "Adverse Events 2:", "- Yeah, that's right."]}